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Objectives: Apoptosis-Inducing Factor (AIF) is a protein involved in mitochondrial electron transport chain assembly/stability and programmed
cell death. The relevant role of this protein is underlined because mutations altering mitochondrial AIF properties result in acute pediatric
mitochondriopathies and tumor metastasis. By generating an original AIF-deficient mouse strain, this study attempted to analyze, in a single
paradigm, the cellular and developmental metabolic consequences of AIF loss and the subsequent oxidative phosphorylation (OXPHOS)
dysfunction.
Methods: We developed a novel AIF-deficient mouse strain and assessed, using molecular and cell biology approaches, the cellular, embryonic,
and adult mice phenotypic alterations. Additionally, we conducted ex vivo assays with primary and immortalized AIF knockout mouse embryonic
fibroblasts (MEFs) to establish the cell death characteristics and the metabolic adaptive responses provoked by the mitochondrial electron
transport chain (ETC) breakdown.
Results: AIF deficiency destabilized mitochondrial ETC and provoked supercomplex disorganization, mitochondrial transmembrane potential
loss, and high generation of mitochondrial reactive oxygen species (ROS). AIF-/Y MEFs counterbalanced these OXPHOS alterations by mito-
chondrial network reorganization and a metabolic reprogramming toward anaerobic glycolysis illustrated by the AMPK phosphorylation at Thr172,
the overexpression of the glucose transporter GLUT-4, the subsequent enhancement of glucose uptake, and the anaerobic lactate generation. A
late phenotype was characterized by the activation of P53/P21-mediated senescence. Notably, approximately 2% of AIF-/Y MEFs diminished both
mitochondrial mass and ROS levels and spontaneously proliferated. These cycling AIF-/Y MEFs were resistant to caspase-independent cell death
inducers. The AIF-deficient mouse strain was embryonic lethal between E11.5 and E13.5 with energy loss, proliferation arrest, and increased
apoptotic levels. Contrary to AIF-/Y MEFs, the AIF KO embryos were unable to reprogram their metabolism toward anaerobic glycolysis. Het-
erozygous AIFþ/- females displayed progressive bone marrow, thymus, and spleen cellular loss. In addition, approximately 10% of AIFþ/- females
developed perinatal hydrocephaly characterized by brain development impairment, meningeal fibrosis, and medullar hemorrhages; those mice
died 5 weeks after birth. AIFþ/- with hydrocephaly exhibited loss of ciliated epithelium in the ependymal layer. This phenotype was triggered by
the ROS excess. Accordingly, it was possible to diminish the occurrence of hydrocephalus AIFþ/- females by supplying dams and newborns with
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Original ArticleConclusions: In a single knockout model and at 3 different levels (cell, embryo, and adult mice) we demonstrated that by controlling the
mitochondrial OXPHOS/metabolism, AIF is a key factor regulating cell differentiation and fate. Additionally, by providing new insights into the
pathological consequences of mitochondrial OXPHOS dysfunction, our new findings pave the way for novel pharmacological strategies.
 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SOD1 Superoxide dismutase 1
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WT Wild-type1. INTRODUCTION
Mitochondria are wide-ranging organelles that through oxidative
phosphorylation (OXPHOS) play a key role in the cell by providing
energy in the form of ATP and by generating the reactive oxygen
species (ROS), which regulate differentiation and fate [1e6]. During
OXPHOS, fuel substrates are oxidized and electrons transferred
through the mitochondrial electron transfer chain (ETC), a branched
chain of multiprotein complexes (complex I to IV). This process is
chemiosmotically coupled to the phosphorylation of ADP to ATP by the
ATP synthase (complex V). Mitochondrial ROS arise from the 0.1%e
2% of electrons that escape from the ETC [7]. The most accepted
model of ETC organization is the so-called “plasticity model,” which
proposes different stable interactions between complexes (e.g., I and
III; or I, III, and IV) in entities named mitochondrial supercomplexes
(SCs) [8,9].
AIF is a bifunctional protein, encoded by Aifm1 (Pdcd8) on the X
chromosome and implicated in maintaining a functional mitochondrial
OXPHOS and, after its translocation to the nucleus, in programmed cell
death (PCD) [10e24]. The role of AIF in mitochondrial complexes
assembly seems to relate to its interaction with CHCHD4, a component
of the mitochondrial protein import machinery [12,13]. In this manner,
AIF or CHCHD4 mutations are concomitant with OXPHOS deficiency-
related mitochondriopathies (encephalopathy, infantile motor neuron
disease, and early prenatal ventriculomegaly) [25e28]. Moreover, the
mitochondrial role of AIF is critical for the inhibition of tumor metastasis
[29], and AIF overexpression aggravates hypoxic-ischemic brain injury
in neonatal mice [30].
The role of AIF has been mainly assessed in the hypomorphic Harlequin
(Hq) mice strain, which is not an AIF KO mouse but presents2 MOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. Tapproximately 70% ubiquitous reduction in AIF expression [10]. Among
others, the Hq strain exhibits T-cell development defaults, chronic
neurodegeneration, progressive cerebellar ataxia, Purkinje cell
degeneration, optic tract dysfunction, early fur abnormalities, and
hypertrophic cardiomyopathy [10,16,17,31e33]. Studies on AIF have
been complemented by the characterization of tissue-specific
knockout models that corroborated T-cell developmental alterations,
delayed neurogenesis, skeletal muscle atrophy, and dilated cardio-
myopathy [14,15,34]. Finally, in a novel mouse model in which Aifm1
was ablated early during hematopoiesis, we observed hematopoietic
stem cell (HSC) loss, thymopoiesis blockade, and delayed development
of the T-cell, B-cell, and erythroid lineages [35,36].
Here, by generating a bona fide AIF KO mouse strain, we illustrate in a
single model the consequences of the mitochondrial OXPHOS
dysfunction associated with the loss of AIF at the cellular, embryonic,
and adult mice levels. The generation of veritable AIF KO mice dem-
onstrates new metabolic and phenotypic adaptive responses, reveals a
greater role for AIF and mitochondrial OXPHOS in mouse development,
and clarifies the AIF function in caspase-independent PCD.
2. METHODS
2.1. Mice
Mice were housed at the Cordeliers Center animal facility under strictly
controlled, specific-pathogen-free conditions (agreement B75-06-12).
Experiments were performed in accordance with ARRIVE ethical
guidelines and with the approval of the French Ministry of Agriculture
(agreement 1675). Animals were maintained with a rodent diet (R03,
Scientific Animal Food & Engineering Diets) and water was available ad
libitum in a vivarium with a 12-hour lightedark cycle at 22 C. Inhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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specific experiments, dams and newborns were fed a high-fat keto-
genic diet (HFD; Research Diets) supplied or not with riboflavin (5 mg/
100 mL) in drinking water.
Aifm1 floxed mice were generated by flanking the exon 11 of Aifm1
with LoxP sequences by using standard gene-targeting techniques
(Genoway, France). After 15 backcrosses into the C57BL/6J back-
ground, Aifm1 floxed males (Aifm1fl/Y; AIFfl/Y) were crossed with PGK-
Cre females (donated by Yvan Lallemand, Pasteur Institute). This
crossing induced an excision of exon 11 in Aifm1 that resulted in a
frameshift mutation and the creation of a stop codon in exon 12. The
resulting Aifm1þ/ (AIFþ/-) females were identified by genomic PCR
assessment (Supplemental Fig. 1C). For hematological analysis, fe-
males were euthanized at 6 months old. Spleens, lymph nodes,
thymus, and bone marrow were sampled to prepare single cell sus-
pensions by mechanical disruption and passage through a cell strainer.
Absolute cell counts were then assessed.
In embryo studies, AIFþ/- females were crossed with Aifm1þ/Y (AIFþ/Y)
males. E7.5 to E13.5 embryos were dissected with the help of a
stereomicroscope (M80; Leica), and pictures were obtained with an
IC80 HD camera (Leica).
2.2. Generation of AIF-/Y mouse embryonic fibroblasts (MEFs)
To generate AIF-/Y MEFs, AIFfl/Y females were crossed with Rosa26-
CreERT2 males (provided by Dr. Anton Bernes, NCI, Amsterdam, The
Netherlands) [37], and MEFs were generated from a triple E12.5
transgenic male embryo. To obtain AIF-/Y cells, MEFs were treated
overnight with tamoxifen (4-OHT; 1 mM).
2.3. Southern blot
Genomic DNA from WT (Co) and AIF-deficient (AIF-/Y) MEFs (4 days
post-treatment with tamoxifen; 4-OHT) was extracted by using a
Wizard Genomic DNA purification kit (Promega) and digested with Pci1.
The genomic DNA fragments obtained, including those encompassing
exons 7 to 13 of Aifm1, were separated on a 0.8% agarose gel and
transferred to a hybond membrane. The membrane was baked for 2 h
at 80 C to fix DNA and then hybridized with a probe labeled with a
Gene Images AlkPhos direct labeling and detection system kit from GE
Healthcare. The probe, specific to the 3’end of AIF genomic DNA, was
freshly prepared by PCR amplification of genomic DNA by using sense
(intron 12 nucleotides 33070e33098) and reverse (intron 13 nucle-
otides 33433e33459) primers. The membrane was then washed, and
the hybridization pattern was revealed by using CDP star (Amersham).
Images were acquired on a MF-ChemiBIS 4.2 (DNR Bio-Imaging
Systems).
2.4. Mitochondrial and cellular analysis
For mitochondrial ROS, mitochondrial mass, and DJm measure-
ments, MEFs were incubated with MitoSOX (5 mM), Mitotracker Green
(100 nM), or Mitotracker Red (100 nM; ThermoFisher Scientific),
respectively, before assessment in a FACSCanto II (BD Biosciences) of
the total population (10,000 cells). Data were analyzed using FlowJo
software and expressed as MFI (mean fluorescence intensity), which
referred to the fluorescence intensity of each event on average.
Additionally, lysed 15 103 WT and AIF-/Y MEFs or 1 104 cells from
embryos dissociated in trypsin were tested for ATP content with a
luciferin-luciferase kit (Abcam) and expressed as an ATP/ADP ratio or
RLU (relative light units). In some experiments, MEFs were pretreated
with oligomycin (10 mM) before ATP assessment. Measures were
performed on an Infinite M100 PRO plate reader (Tecan).
To analyze glucose assimilation, MEFs were incubated (30 min; 37 C)
in glucose-free DMEM with 2-NBDG (100 mM; ThermoFisher Scientific)MOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.combefore the flow cytometry assessment of the total population (10,000
cells).
Glycolytic and GLUT-4 dependency was verified in MEFs treated or not
with indinavir (50 mM; Selleckchem) or 2-Deoxy-D-Glucose (2-DG;
10 mM); AMPK dependency was verified in MEFs pretreated or not with
dorsomorphin (Compound C; 25 mM; Selleckchem); the induced cell
death rate was assessed by an Annexin-V-APC (0.1 mg/ml; BD Bio-
sciences) and propidium iodide (PI) double labeling on a FACSCanto II
in the total population (10,000 cells).
In cell cycle analyses, MEFs were incubated (30 min; 37 C) with BrdU
(10 mM). After fixation and partial DNA denaturation, cells were co-
stained with an anti-BrdU-FITC antibody (25 mg/mL; BD Biosciences)
and PI before the flow cytometric measurement in the total population
(10,000 cells).
Senescence was recorded in MEFs treated with chloroquine diphos-
phate (300 mM, 2 h) to induce lysosomal alkylinization. Next, C12FDG
(Thermofisher Scientific) was added at 33 mM, and the cells were
washed twice with PBS before performing the cytofluorometric
quantification.
Cell death was assessed by flow cytometry in the total population
(10,000 cells) using Annexin-V-APC (assessment of phosphatidylserine
exposure; 0.1 mg/ml) and PI (cell viability) co-labeling. In some ex-
periments, WT and AIF-/Y MEFs were pretreated 30 min with MNNG
(250 mM, 9 h), staurosporine (STS; 1 mM, 6 h), b-Lapachone (4 mM;
18 h), or etoposide (20 mM, 6 h) before the flow cytometry assessment
of cell death. In caspase-dependent control experiments, MEFs were
pretreated at 30 min with QVD.OPh (1 mM) before etoposide treatment.
For lactate measurement in MEFs, cells were cultured for 2 h in a
serum-free medium and centrifuged. The amounts of lactate in the
supernatants were quantified in the Infinite M100 PRO plate reader by
using the L-lactate kit from Cayman Chemical. Lactate was also
quantified in embryos dissociated in 50 mL of the L-lactate kit assay
buffer. After centrifugation, the quantity of lactate in 10 mL of the
supernatant was assessed.
2.5. Clark electrode
Oxygen consumption was measured in 5 106 WT and AIF-/Y MEFs as
previously described [38]. In non-permeabilized cells, respiration was
measured under basal conditions in a DMEM medium and in response
to the sequential addition of oligomycin (10 mM), fluoro-carbonyl cy-
anide phenylhydrazone (FCCP; 5 mM), amytal (2 mM), and azide
(5 mM). In digitonin-permeabilized cells (1 mg/mL, 5 min), respiration
was measured in response to the sequential addition of glutamate/
malate (10 mM/4 mM), ADP (2 mM), amytal (2 mM), succinate
(10 mM), malonate (10 mM), glycerol-3-phosphate (15 mM), myx-
othiazol (0.5 mM), tetramethyl-phenylenediamine (TMPD)/ascorbate
(0.5 mM/2 mM), and azide (5 mM).
2.6. Mitochondrial supercomplex (SC) assessment
Mitochondria were purified from control (0) or 4-OHT-treated MEFs
(4e16 days post-treatment) and permeabilized by digitonin. Solubi-
lized complexes and supercomplexes were separated by 1D BN-PAGE
and revealed by the NADH dehydrogenase in-gel activity (0.1 mg/ml
NADH and 2.5 mg/ml nitrotetrazolium blue chloride). Alternatively, the
mitochondrial complexes I, III, and IV and the SCs were visualized by
immunoblot using antibodies against NDUFA9 (20C11B11B11, Life
Technologies), UQCRC2 (13G12AF12BB11, Abcam), or COX4I2
(20E8C12, Abcam). Immunoreactive proteins were detected by using
HRP-conjugated secondary antibodies and visualized with an ECL
chemiluminescence kit (Thermo Scientific). Images were acquired by
using the MF-ChemiBIS 4.2 imager.access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
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MEFs seeded on coverslips were fixed in 2% paraformaldehyde (PFA)
and incubated with the mitochondrial marker Mitotracker Red (20 nM;
Thermo Fisher) and the nuclear dye Hoechst 33342. Slides were
imaged by using an LSM 710 Zeiss confocal microscope and analyzed
by ImageJ software.
2.8. Electron microscopy
Control (D0) or tamoxifen-treated MEFs (12e16 days post-treatment)
were fixed at 4 C for 2 h in 2.5% glutaraldehyde in 0.1 M phos-
phate buffer (pH 7.3) postfixed for 1 h in 1% buffered osmium tetroxide,
dehydrated through a graded ethanol series, and embedded in Epon
812. The ultrathin sections were counterstained with 2% aqueous
uranyl acetate for 30 min, and then with lead citrate for 10 min, and
finally viewed under a Philips 100X electron microscope. Alternatively,
freshly dissected E9.5 WT and AIF-/Y embryos were fixed, processed for
ultrathin sections, counterstained, and examined as aforementioned.
2.9. Lentiviral transduction
An in-frame c-terminal tag encoding the V5 epitope was first added to
the AIF-wt cDNA (plasmid pcDNA3.1 mAIFV5). The resulting cDNA was
then subcloned into the pLVX-IRES-Zs-Green lentiviral vector (Clon-
tech-Takara Bio Europe). Viruses were produced in 293T cells by CaCl2
transient transfection of the lentiviral constructs and the packaging
plasmids pCMV-VSV-G and pCMV-dR8.2 dvpr (Addgene plasmids
8454 and 8455, respectively) [39]. Forty-eight hours after transfection,
lentiviral supernatants were harvested, clarified by filtration, and used
immediately for AIF-/Y MEFs transduction with 6 mg/ml of polybrene.
Seventy-two hours after transduction, GFP positive cells were sorted
and expanded, and the AIF location and mitochondrial network dis-
tribution were visualized by immunofluorescence as aforementioned.
2.10. Immunoblotting
MEFs or freshly dissected embryos were lysed in buffer containing
50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and
the protease/phosphatase inhibitor cocktail from Roche. Protein con-
centration was determined by using the BioRad Protein Assay. Equal
amounts of total proteins (50 mg) were loaded on linear SDS-PAGE gels
and transferred onto a PVDF or nitrocellulose membrane. Membrane
blocking and antibody incubations were performed in TBS 0.1% Tween
20 plus 5% nonfat dry milk. The primary antibodies used were AIF (D-
20, Santa Cruz), NDUFA9 (20C11B11B11, Life Technologies), NDUFS3
(3F9DD2, Life Technologies), SDHA (2E3GC12FB2AE2, Life Technol-
ogies), UQCRC2 (13G12AF12BB11, Abcam), COX1 (35e8100; Thermo
Fisher), COX4I2 (20E8C12, Abcam), ATP5B (3D5AB1, Life Technolo-
gies), AMPKalpha (Cell signaling) and phospho-AMPKalpha (Thr172,
Cell signaling), p21Cip1 (C-19, Santa Cruz), Phospho-Rb (Cell
Signaling), and b-Actin (AC15, Sigma). Immunoreactive proteins were
detected by using HRP-conjugated secondary antibodies and visual-
ized with SuperSignal West Dura chemiluminescence kits (Thermo
Scientific). Immunoblot images were acquired in the MF-ChemiBIS 4.2
imager.
Brains from the WT, AIF-/X, and AIF-/X HC females were dissected and
frozen in liquid nitrogen and used for protein carbonyls detection. After
the generation of brain homogenates (2 mg), biotin-hydrazide (60 mM),
sodium cyanoborohydride (30 mM), and trichloroacetic acid (10%)
were successively added to the samples. After centrifugation, pellets
were washed with 1:1 ethanol/ethyl acetate and dissolved in Laemmli
buffer. Next, equal amounts of total proteins (50 mg) were loaded on
linear SDS-PAGE gels and transferred onto a PVDF membrane. Protein
carbonyls were visualized by using streptavidin-HRP revealed by4 MOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. Tchemiluminescence and quantified by using Multi Gauge 3.0 software
(Fujifilm Life Sciences). The optical density was normalized according
to an endogenous background and was expressed relative to the data
obtained in untreated cells (¼ 1.0).
2.11. Quantitative RT-PCR
Total RNA from the cells, embryos, or brain was extracted by using a
Nucleospin RNA II kit (MachereyeNagel). cDNA was prepared by
using Superscript II reverse transcriptase (Life Technologies).
Quantitative RT-PCR was performed by using TaqMan Gene
Expression Assays (Life Technologies) for Mfn1 (mitofusin 1), Mfn2
(mitofusin 2), Opa1 (mitochondrial dynamin-like GTPase), Fis1 (mito-
chondrial fission 1 protein), Dnm1l (dynamin-related protein 1), Mff
(mitochondrial fission factor), Sod1 (Super oxide dismutase 1), Sod2
(Super oxide dismutase 2), Glut-1 (Slc2a1, solute carrier family 2
[facilitated glucose transporter], member 1), Glut-4 (Slc2a4, solute
carrier family 2 [facilitated glucose transporter], member 4), Tp53
(tumor protein p53), Cdkn1a (cyclin-dependent kinase inhibitor 1A,
P21), or Pgc1a (Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha). PCR reactions were performed in triplicate by
using TaqMan Fast advanced Master Mix (Life Technologies). The
products were amplified in a ViiA7 Real-time PCR System (Life
Technologies) at 60 C for 40 cycles. Data were evaluated by the
comparative threshold cycle method. The housekeeping expression of
18S was used to normalize the data.
2.12. Histology
We developed a specific method of embedding without prior macro-
scopic dissection of the brain to observe both neural tissue with brain
envelope and the skull bone on the same histology slide. Wild-type
(WT) and AIF-/X hydrocephalus (HC) females were fixed by perfusion
in 4% PFA. After decalcification with 0.1 N nitric acid and paraffin
embedding, 4 mm thick sections were stained with hematoxylin-eosin.
Some tissues were processed without paraffin embedding before
vibratome sectioning (for 100 mm thick floating sections). E9.5 WT and
AIF-/Y embryos were fixed in 4% PFA and embedded in acrylic resin
(historesin acrylic Leica) before 3 mm sectioning and hematoxylin-
eosin staining. Images were obtained by using a Leica
photomicroscope.
2.13. Immunohistochemistry
Brains of WT and AIFþ/- HC females were fixed in 4% PFA. After
decalcification, free-floating brain sections (100 mm) were fixed in PFA
before performing the immunostaining with anti-Iba1 (1:100 Dako). We
used a long incubation process (24 h) after deterging the lipid with high
concentration triton X (1%). Nuclei were counterstained with the nu-
clear dye Hoechst 33342. Slides were imaged by using an LSM 710
Zeiss confocal microscope and analyzed by using the ImageJ software.
The activities of cyclooxygenase (COX) and succinate dehydrogenase
(SDH) were visualized to explore respiratory dysfunction in embryos
[40]. Briefly, E9.5 WT and AIF-/Y embryos were dissected, placed in a
plastic mold containing cold optimal cutting temperature (OCT) com-
pound, and snap-frozen in liquid nitrogen. Fourteen mm cryosections,
obtained by using cryostat CM 3050S (Leica), were incubated for
40 min at 37 C with 3,30-diaminobenzidine tetra-hydrochloride,
500 mM cytochrome c, and bovine catalase. The sections were then
washed 4 times for 10 min in 0.1 M PBS (pH 7.0). Next, 1.875 mM
nitroblue tetrazolium (NBT), 1.30 M sodium succinate, 2.0 mM
phenazine methosulfate, and 100 mM sodium azide were applied for
40 min at 37 C. Sections were finally washed, cover-slipped, and
visualized under bright field microscopy.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: AIF loss led to ETC dysfunction and mitochondrial network disorganization. (A) To generate AIF-/Y MEFs, we crossed the Rosa26-CreERT2 mice with the Aifm1
floxed strain [35]. Among the embryos, E12.5 AIFFl/Y; RosaCre ERT2þ/ embryos were genetically identified and dissected. After MEFs generation and expansion, cells were treated
overnight with tamoxifen (4-OHT; 1 mM) to induce Aifm1 exon 11 excision [35]. (B) Representative time-course immunoblot of untreated (0) or 4-OHT-treated MEFs (1e18 days
post-treatment) revealing the progressive loss of AIF and key proteins of the ETC complexes I and IV. Equal loading was confirmed by b-Actin probing. This experiment was
repeated three times with similar results. (C) Multiprotein complex assessment by blue native polyacrylamide gel electrophoresis (BN-PAGE) in mitochondria purified from control
(0) or 4-OHT-treated MEFs (4e16 days post-addition). Up to down gel pictures: (i) Mitochondrial complex I and complex I-containing supercomplexes visualized by immunoblot
(NDUFA9); (ii) Representative result of an NADH dehydrogenase complex I in-gel test revealing ETC supercomplex disorganization after AIF loss; (iii) and (iv) Complex III dimer
(UQCRC2) and IV monomer (COX4I2) detected by immunoblot. This experiment was repeated five times with similar results. (D) Analysis of the mitochondrial network changes
associated with AIF loss. Upper panels, representative immunofluorescence images of control (D0), and AIF-/Y MEFs (D12 and D16) labeled with Mitotracker Red (mitochondria) and
Hoechst (nucleus). Bar: 100 mm. Lower panels, control (D0), and AIF-/Y MEFs (D12 and D16) analyzed by electron microscopy. Representative microphotographs are shown. Black
squares underline mitochondrial features. Bar: 0.5 mm. (E) Mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), mitochondrial dynamin-like GTPase (Opa1), mitochondrial fission 1 protein (Fis1),
dynamin-related protein 1 (Dnm1l), and mitochondrial fission factor (Mff) mRNA levels determined by quantitative RT-PCR in control (D0) and AIF-/Y MEFs (D12; n ¼ 4). 18S mRNA
expression was used to normalize data. Results are expressed as a ratio of mRNA expression relative to control (D0) cells (set at 1.0). (F) Flow cytometry DJm assessment
performed by Mitotracker Red labeling in control (D0) and AIF-/Y MEFs (D16) and expressed as a plot (n ¼ 8). Data were obtained in 10,000 cells and expressed as mean
fluorescence intensity (MFI). (G) Mitochondrial ROS levels recorded in control (D0) and AIF-/Y MEFs (D16) and graphed (n ¼ 9). Data were obtained in 10,000 cells and expressed as
mean fluorescence intensity (MFI). (H) Sod1 and Sod2 mRNA levels determined by quantitative RT-PCR in control (D0) and AIF-/Y MEFs (D16; n ¼ 5). 18S mRNA expression was
used to normalize data. Results are expressed as a ratio of mRNA expression relative to control (D0) cells (set at 1.0). (I) ATP/ADP ratio recorded in control (D0) and AIF-/Y MEFs
(D16) left untreated or pre-treated with oligomycin (10 mM; n ¼ 7). Results are expressed as a ratio of ATP/ADP relative to control (D0) cells (considered as 100%). Statistical
significance was calculated by ManneWhitney (E, H) or student t (F, G, I) tests. Bars represent mean  SEM.To evaluate proliferation in embryos, pregnant females were intra-
peritoneally injected with BrdU (0.1 mg BrdU/g of body weight) 1 h
before embryonic dissection. E8.5 and E9.5 WT and AIF-/Y embryos
were identified by PCR, dissected, and kept in separated well plates in
ice-cold PBS/BSA 0.4%. After fixation in ice-cold EtOH (70%; H2O)
overnight, embryos were rehydrated with ice-cold EtOH 50% for
15 min at 4 C and then washed with ice-cold PBS/BSA 0.4%. Em-
bryos were then submerged in sucrose 30% (diluted in phosphate
buffer 0.1 M, pH 7.4) until they reached the bottom of the well. Next,
embryos were placed in molds containing cold OCT and snap-frozen in
liquid nitrogen. Further, 10e12 mm cryosections were made by using
the cryostat CM 3050S and processed for BrdU immunostaining.MOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comBriefly, sections were quenched with H2O2 0.6% and MetOH 1% in PBS
for 1 h at RT. After washing, slides were unmasked with HCl 3.7% and
processed with sodium borate 0.1 M. After a pre-blocking step, an
anti-BrdU antibody (BD Biosciences) was added on top of each section
and a secondary biotinylated antibody was added. Slides were next
incubated with streptavidin-488 and Hoechst. Images were obtained
on a fluorescent microscope Axiovert 200M (Zeiss).
For embryonic cell death detection, E8.5 and E9.5 WT and AIF-/Y
embryos were dissected, fixed in PFA (4%), embedded in cold OCT and
snap-frozen in liquid nitrogen. Next, 10e12 mm cryosections, made
with the cryostat CM 3050S, were fixed in methanol/acetic acid so-
lution (2:1) at 20 C. After permeabilization, TUNEL mix (Rocheaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Original ArticleDiagnostics) was added on top of each section for 1 h at 37 C. After 2
washing steps, nuclei were colored by Hoechst 33342. Images were
obtained on a fluorescent microscope Axiovert 200M (Zeiss) using
transmitted light.
2.14. Statistics
The results, displayed as mean  SEM, were statistically analyzed by
the ManneWhitney or student t tests by using GraphPad Prism soft-
ware. Significant p values were indicated as follows: *p  0.05,
**p  0.01, and ***p  0.001. All experiments were independently
repeated at least 3 times.
Chemicals and reagents were purchased from SigmaeAldrich except
where otherwise noted.
3. RESULTS
3.1. AIF-/Y MEFs were OXPHOS defective and showed extensive
ETC supercomplex disorganization
To analyze mitochondrial and cellular alterations associated with AIF
loss, we generated a primary mouse embryonic fibroblasts knockout
(KO) for AIF (AIF-/Y MEFs) by crossing Rosa26-CreERT2 mice [37] with
our novel Aifm1 floxed strain (Figure 1A and Supplemental Fig. 1).
Tamoxifen (4-OHT) treatment of AIFFl/Y was conducted; RosaCre
ERT2þ/ MEFs provoked progressive AIF protein loss (Figure 1B),
which destabilized mitochondrial ETC complexes I and IV (e.g., loss of
NDUFA9, NDUFS3, and COX4I2 proteins). Complexes II, III, and V (ATP
synthase) remained unaltered (Figure 1B). Complementary blue native
polyacrylamide gel electrophoresis (BN-PAGE) and immunoblot as-
sessments revealed that AIF deficiency, in addition to a strong
reduction in free complex I levels, also provoked ETC SC disorgani-
zation with a rapid loss of complex I2þ complex III2 and triple complex
I þ complex III2 þ complex IV structures and a more delayed
disruption of complex I þ complex III2 organization (Figure 1C). These
observations are in accordance with the “plasticity” model of ETC
structure in which the alteration of individual complexes directly affects
the supercomplex organization [8,9,41].
Analysis of the oxygen consumption rate confirmed that mitochondrial
respiration was significantly altered in AIF-/Y MEFs. As described in
Supplemental Fig. 2A, compared to control MEFs (cells before 4-OHT
treatment; D0), AIF-/Y MEFs (16 days after tamoxifen treatment; D16)
exhibited a significant reduction of oxygen consumption in both
phosphorylating (basal) and non-phosphorylating (þoligomycin) con-
ditions. The total oxidative capacity, assessed by the presence of the
ionophore FCCP, was also compromised in KO cells. Treatment with
the complex I inhibitor amytal abolished the remaining oxygen con-
sumption of AIF-/Y MEFs, indicating that complex I remained slightly
functional. Finally, analysis of the individual complex activities revealed
that complexes I to IV’s activities were affected by AIF deficiency
(Supplemental Fig. 2B).
Mitochondrial labeling revealed that the kinetic of AIF disappearance
was linked to the progressive disruption of the mitochondrial network
(Figure 1D, upper panels). Remarkably, at D12 after tamoxifen, elec-
tronic microscopy pictures uncovered elongated mitochondria, sug-
gesting a mitochondrial fusion development (Figure 1D, lower panels).
This finding is substantiated by the quantitative RT-PCR analysis of
central executioners of mitochondrial dynamics. Indeed, as depicted in
Figure 1E, in contrast to the fission factors FIS1, DNM1L (DRP1), and
MFF, the mRNA of the key members of the fusion machinery MFN1,
MFN2, and OPA1 appeared significantly overexpressed in these AIF-/Y
MEFs. Thus, although the inhibition of the mitochondrial fission6 MOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. Tmachinery could also contribute to the elongated mitochondrial
phenotype observed in the AIF-/Y MEFs at D12 after tamoxifen treat-
ment, our multiparametric assessment points toward the prevalence of
a transient mitochondrial fusion process.
Further, upon complete AIF disappearance (D16 after tamoxifen
treatment), we observed a highly fragmented mitochondrial network
associated with cellular vacuolization (Figure 1D). These alterations
provoked a significant decrease in the cellular mitochondrial trans-
membrane potential and a high generation of mitochondrial ROS
(Figure 1F,G). The excess ROS triggered mRNA overexpression of
mitochondrial SOD2 (Superoxide dismutase 2), a protein that partially
regulated the excess superoxide OXPHOS products (Figure 1H). Sur-
prisingly, despite mitochondrial dysfunction, ATP levels were relatively
preserved in AIF-/Y MEFs (Figure 1I). One possible explanation for this
finding is that MEFs normally generate ATP by non-mitochondrial
pathways. Alternatively, a possibility is that AIF KO MEFs have
reprogrammed their metabolism to counterbalance mitochondrial
OXPHOS dysfunction. To evaluate this dichotomy, we treated control
and AIF-/Y MEFs with oligomycin, which specifically blocks the mito-
chondrial ATP synthase and thus inhibits the generation of mito-
chondrial ATP. In control MEFs, oligomycin treatment dramatically
diminished ATP levels, indicating that these cells generate most of the
ATP through mitochondria. By contrast, oligomycin marginally modified
ATP levels in AIF-/Y MEFs, suggesting that these cells generate ATP
through a non-mitochondrial pathway (Figure 1I). Those results sug-
gest that AIF-/Y MEFs were able to modify their metabolism to
compensate the mitochondrial OXPHOS dysfunction.
3.2. OXPHOS damage associated with AIF deficiency was
counterbalanced by a shift toward anaerobic glycolysis and
development of a senescent phenotype
Based on our results thus far, the next step was to analyze the
mechanism associated with the adaptive metabolic features of AIF-/Y
MEFs. More precisely, by measuring the phosphorylation of AMPK at
Thr172 and the mRNA expression of the main glucose transporters
expressed in fetal tissues and fibroblasts (GLUT-1 and GLUT-4), we
first assessed whether the AIF loss was accompanied by a modification
in the glucose assimilation pathway. Phosphorylation of AMPK, a
central regulator of energy homeostasis, is a point of convergence of
metabolic and genomic stress signals [42e45]. Indeed, AMPK is a
major energy-sensing kinase that plays a role in cellular energy ho-
meostasis by activating a variety of catabolic processes in multicellular
organisms, such as glucose uptake and metabolism. More precisely,
among others, phosphorylated AMPK stimulates glucose uptake by
modulating GLUT-4 plasma membrane function [46e49]. As
described in Figure 2A,B, the loss of AIF was associated with a sig-
nificant and specific kinetic phosphorylation/activation of AMPK at
Thr172 and the subsequent mRNA overexpression of Glut-4, not Glut-
1. This finding suggested an enhancement of glucose uptake mediated
by GLUT-4, which was further substantiated by the blockade of 2-
NBDG assimilation by the specific GLUT-4 inhibitor indinavir
(Figure 2C).
The measurement of lactate release, a marker of anaerobic glycolysis,
indicated that AIF-/Y compensated for the mitochondrial OXPHOS
dysfunction through the reinforcement of this glycolytic pathway
(Figure 2D). Notably, the anaerobic glycolytic shift appeared to be
sufficient to maintain ATP levels (Figure 1I) and preserve AIF-/Y viability
(absence of cell death), which surprisingly remained very close to
those of control (D0) MEFs (Figure 2E). The central role of AMPK and
GLUT-4 in the enhancement of the glucose metabolism and the
preservation of ATP levels and cell viability in the AIF KO MEFs washis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Mitochondrial OXPHOS dysfunction was counterbalanced in AIF-/Y MEFs by a shift towards anaerobic glycolysis and the development of a senescent
phenotype. (A) Kinetic phosphorylation of AMPK visualized by immunoblot in left untreated (0) or 4-OHT-treated MEFs (4e16 days post-treatment). Equal loading was confirmed
by b-Actin probing. This experiment was repeated three times with similar results. (B) Glut-1 and Glut-4 mRNA levels determined by quantitative RT-PCR in control (D0) and AIF-/Y
MEFs (D12 and D16; n ¼ 8). 18S mRNA expression was used to normalize data. Results are expressed as a ratio of mRNA expression relative to control (D0) cells (set at 1.0). (C)
Glucose uptake measured by the assimilation of 2-NBDG in control (D0) and AIF-/Y MEFs (D12 and D16) untreated or pre-treated with indinavir (50 mM; n ¼ 6). Results are
expressed as a ratio relative to control (D0) cells (set at 1.0). (D) Lactate release, recorded in control (D0) and AIF-/Y MEFs (D12 and D16), was measured as described in the
Methods section (n ¼ 4). (E) Cytofluorometric assessment of cell death performed in control (D0) and AIF-/Y MEFs (D12 and D16) untreated or pre-treated with indinavir (50 mM)
and labeled with AnnexinV and PI. The frequency of positive staining, which represents dying cells, was recorded and expressed as a plot (n ¼ 6). (F) Flow cytometry cell cycle
analysis performed in control (D0) and AIF-/Y MEFs (D12 and D16) by BrdU and PI (DNA content) co-labeling. Left, representative cytometric panels of control (D0) and AIF-/Y MEFs
(D16). Right, the percent of cells in phase S was quantified and expressed as a plot (n ¼ 4). (G) Cytometric evaluation of senescence in control (D0) and AIF-/Y MEFs (D12 and D16)
using the b-galactosidase substrate C12FDG. Representative flow cytometric profiles of control (D0) and AIF-/Y MEFs (D16). (H) The percentage of C12FDG positive control (D0) and
AIF-/Y MEFs (D12 and D16) measured as in (G) was calculated and graphed (n ¼ 4). (I) Tp53 mRNA levels determined by qPCR in control (D0) and AIF-/Y MEFs (D12 and D16;
n ¼ 5). 18S mRNA expression was used to normalize data. Results are expressed as a ratio of mRNA expression relative to control (D0) cells (set at 1.0). (J) Left, Cdkn1a mRNA
levels determined by qPCR in control (D0) and AIF-/Y MEFs (D12 and D16; n ¼ 6). 18S mRNA expression was used to normalize data. Results are expressed as a ratio of mRNA
expression relative to control (D0) cells (set at 1.0). Right, representative immunoblot of control (D0) and AIF-/Y MEFs (D12 and D16) revealing the cell cycle inhibitor P21. Equal
loading was confirmed by b-Actin probing (n ¼ 4 experiments with similar results). (K) Representative immunoblot of control (D0) and AIF-/Y MEFs (D12 and D16) revealing the
decrease in pRb phosphorylation (P-pRb) associated with AIF loss. Equal loading was confirmed by b-Actin probing (n ¼ 3 experiments with similar results). Statistical significance
was calculated by ManneWhitney (D, F, H, I) or student t (B, C, E, J) tests. Bars represent mean  SEM.corroborated by the pharmacological inhibition of AMPK or GLUT-4 by
dorsomorphin and indinavir, respectively [50,51]. As described in
Supplemental Figs. 3 and 2E, AMPK inhibition precluded Glut-4 mRNA
overexpression and both Glut-4 mRNA downregulation and inhibition of
GLUT-4-mediated glucose uptake/metabolism induced cell death in
the AIF KO MEFs. Altogether, these results corroborated that the AIF-/Y
MEFs counterbalance the mitochondrial OXPHOS dysfunction by
reprogramming their metabolism toward anaerobic glycolysis through
an AMPK/GLUT-4 adaptive mechanism.
We next investigated whether the lack of cell death in AIF-/Y MEFs was
linked to cell cycle alterations. As demonstrated by BrdU/PI co-
staining, contrary to what was reported in embryonic stem cells
[52], the loss of AIF provoked cell cycle and cell proliferation arrest inMOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comMEFs. More precisely, compared to control MEFs (D0), in which
approximately 15%e20% of the cell population was in the proliferative
S cell cycle phase, the D12 and D16 AIF KO MEFs showed less than
5% of the population in the S phase (Figure 2F). Surprisingly, the arrest
of cell proliferation recorded in AIF-/Y MEFs appeared to be associated
with the kinetic activation of a ROS/P53/P21-mediated senescence
pathway [53,54], as confirmed by specific C12FDG senescent b-
galactosidase staining (with more than 60% positive senescent la-
beling at D16) and mRNA overexpression of the ROS-induced genetic
markers Tp53 and Cdkn1a (Figure 2F,G, H, I, and J). Notably, Cdkn1a
expression is tightly controlled by Tp53, and Cdnk1a codes for P21, a
potent cyclin-dependent kinase inhibitor [55]. As expected, the kinetic
Tp53 and Cdkn1a mRNA overexpression provoked the progressive up-access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 3: Lentiviral transduction of AIF-/Y MEFs with V5 tagged AIF-wt cDNA restored normal mitochondrial OXPHOS/metabolism and corroborated the specific role of
AIF in MNNG- and b-Lapachone-mediated cell death. (A) Representative confocal images of AIFþ/Y (WT), AIF-/Y (AIF KO), and AIF-/Y expressing AIF-wt MEFs (AIF KO þ AIF-V5)
labeled with MitoTrackerRed (mitochondria) and Hoechst (nucleus), corroborating that lentiviral transduced AIF-V5 relocalized into mitochondria and reconstituted the mitochondrial
network. Bar: 100 mm. (B) Representative immunoblot of the panel of MEFs used in (A) demonstrating the presence of AIF and key proteins of the ETC complexes I to V after the
lentiviral transduction of AIF-V5 into the AIF-/Y MEFs. Equal loading was confirmed by b-Actin. This experiment was repeated 5 times with similar results. (C) Mitochondrial
supercomplex picturing of WT, AIF KO, and AIF KO þ AIF-V5 was performed by 1D BN-PAGE, such as in Figure 1C. Mitochondrial supercomplexes and complex I were detected by
NDUFA9 immunoblotting, complex III (dimer) was visualized by UQCRC2 blotting. This experiment was repeated 3 times with similar results. (D) Assessment of basal (coupled) and
maximal respiration (uncoupled) in WT, AIF KO, and AIF KO þ AIF-V5 MEFs by using a Clark’s electrode. Basal respiration corresponds to O2 consumption rate coupled to ATP
production, whereas sequential addition of 10 mM oligomycin (ATP synthase inhibitor), 15 mM fluoro-carbonyl cyanide phenylhydrazone (FCCP; uncoupling agent measuring the
maximal respiration capacity), 2 mM amytal (complex I inhibitor), or 5 mM sodium azide (mitochondrial OXPHOS inhibitor) enable calculation of the maximal oxygen consumption
rate. The percent of activity (relative to that measured in WT cellsdconsidered as a 100%) in coupled and uncoupled conditions was expressed as a histogram (n ¼ 5 independent
experiments). Notably, the lentiviral transduction of AIF-V5 into the AIF KO MEFs fully restored mitochondrial respiration. (E) Glucose uptake measured by assimilation of 2-NBDG in
WT, AIF KO, and AIF KO þ AIF-V5 MEFs (n ¼ 4). Results are expressed as a ratio of mRNA expression relative to control (D0) cells (set at 1.0). (F) Lactate release recorded in WT,
AIF KO, and AIF KO þ AIF-V5 MEFs as described in the Methods section (n ¼ 4). (G) The panel of MEFs used in (A) to (F) were untreated or treated with 2-Deoxy-D-Glucose (2-DG;
10 mM; 24 h) and labeled with AnnexinV and PI. The frequency of positive staining, which represents dying cells, was recorded and expressed as a plot (n ¼ 4). (H) The panel of
MEFs used in (A) to (F) was untreated or treated with N-methyl-N0-nitro-N0-nitrosoguanidine (MNNG; 250 mM; 9 h), staurosporine (STS; 1 mM; 6 h), b-Lapachone (4 mM; 18 h), or
etoposide (20 mM; 6 h) in the absence or presence of the broad caspase inhibitor QVD.OPh (1 mM). Next, MEFs were labeled with AnnexinV and PI, and the frequency of positive
staining, which represents dying cells, was recorded and graphed (n ¼ 6). Statistical significance was calculated by ManneWhitney (D, E, F, G) or student t (H) tests. Bars
represent mean  SEM.
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regulation of the P21 protein (Figure 2J). P21 induction by means of
cyclin-dependent kinase CDK2 and CDK4/6 inhibition leads to
dephosphorylation/activation of retinoblastoma protein (pRB;
Figure 2K), a well-established cell cycle regulator that in a non-
phosphorylated state inhibits cell cycle progression [55e58]. Indeed,
ROS-induced senescence can be identified in vitro by the increased
expression of genes/proteins associated with cell cycle arrest (e.g.,
P53 and P21), pRB dephosphorylation/activation, and presence of
senescence-associated b-galactosidase activity, which is attributed to
the high lysosomal content of senescent cells [59]. All these features
characterized AIF-/Y MEFs.
3.3. AIF-/Y MEFs were resistant to caspase-independent cell death
After remaining senescent for days, approximately 2% of AIF-/Y MEFs
spontaneously proliferated. The analysis of these proliferating cells
indicated that compared to the senescent AIF-/Y MEFs, cycling AIF KO
MEFs diminished the mitochondrial mass and the ROS levels. This
finding was correlated to the loss of P21 expression and the subse-
quent phosphorylation/inactivation of pRb that favors cell cycle pro-
gression (Supplemental Fig. 4). These results support the relationship
between ROS generation and P21/pRb-mediated cell cycle arrest in the
senescent AIF KO cells.
We used proliferating AIF KO MEFs to analyze, among others, the
PCD capacities of AIF-/Y cells. To generate a reliable control, we
reintroduced the AIF-wt cDNA (V5 tagged) into the AIF-/Y MEFs by
lentiviral transduction (AIF KO þ AIF-V5 MEFs). AIF KO þ AIF-V5
MEFs incorporated AIF into the mitochondria, rescued the normal
mitochondrial network (Figure 3A), and reconstituted the ETC pro-
teins (Figure 3B) and SC patterns (Figure 3C). The functionality of
mitochondrial OXPHOS in the AIF KO þ AIF-V5 MEFs was substan-
tiated by oxygen consumption tests (Figure 3D). Finally, the glycolytic
adaptive phenotype of AIF-/Y MEFs was disabled by the lentiviral AIF
transduction (Figure 3E,F). Concerning sensitivity to PCD, contrary to
primary (WT) and the reconstituted AIF KO þ AIF-V5 MEFs, AIF-/Y
MEFs were sensitive to the glycolytic inhibitor 2-Deoxyglucose
(Figure 3G), underlining its glucose dependency. Additionally, cell
lines were exposed to different PCD inducers: MNNG and b-Lapa-
chone (caspase-independent PCD inducers) [10,18,20,21,60], STS (a
cytotoxic inducer partially controlled by caspase activation), and
etoposide (a typical caspase-dependent agent) [61e63]. As depicted
in Figure 3H, AIF-/Y MEFs were highly resistant to MNNG and b-
Lapachone, partially resistant to STS, and sensitive to etoposide. We
corroborated that the pretreatment of MEFs with the broad caspase
inhibitor (QVD.OPh) inhibited etoposide-mediated killing. Finally, as
expected, reintroduction of AIF into the AIF-/Y MEFs fully re-sensitized
these MEFs to MNNG, b-Lapachone, and STS. Altogether, these
results substantiate the specific role of AIF in caspase-independent
cell death and corroborate the literature that has described the
limited response of AIF-deficient MEFs to STS [14,21]. Finally, those
data indicate that AIF-/Y MEFs remain sensitive to caspase-dependent
PCD inducers.
3.4. A significant percentage of AIFþ/- females developed a
hydrocephalus phenotype and exhibited immune cell exhaustion
To extend our study toward an in vivo model, we crossed Aifm1 floxed
males (AIFFl/Y) with a PGK-Cre strain, which is a driver of Cre
recombinase expression very early during embryonic development
[64]. This crossbreeding yielded heterozygous female offspring (AIFþ/-)
in a Mendelian distribution (Figure 4A). Most of the AIFþ/- animals did
not present external phenotypic changes until they reached 6 months
of age, at which stage we detected a significant diminution of boneMOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.commarrow, spleen, and thymus cellularity (Supplemental Fig. 5). Sur-
prisingly, approximately 10% of AIFþ/- females (5% of total newborns)
developed a perinatal hydrocephalus phenotype (visible in 2-week-old
animals) characterized by an enlarged and dome-shaped head and
accompanied by a progressive loss of mobility (Figure 4A). These
animals died 4/5 weeks after birth.
Compared to control animals, the brain of AIFþ/-hydrocephalus ani-
mals (AIFþ/- HC) showed an excess of cerebrospinal fluid (CSF) that
warped the brain (right microphotographs in Figure 4A). Hematoxylin/
eosin staining of the mice and head sections provided insights into the
extent to which the CSF compressed the cerebral mass into the
cranial cavity (Figure 4B, left microphotographs). In coronal sections,
we observed severe thinning of the brain ventricular wall with an
enlargement of the lateral ventricles and meningeal fibrosis
(Figure 4B, right panels). Brain development, apart from the
compression, seemed normal. Some mice showed a dilated third
ventricle and a herniated cerebellum. We also observed strong spinal
and parenchymatous hemorrhages. Circulating macrophages
engorged with blood could be observed in some sections of the
ependymal epithelium (Figure 4C). This epithelium, lining the ven-
tricular cavities, is normally composed of a single cell layer. In the
case of AIFþ/- HC, the ependymal epithelium lining the ventricles was
abnormal with visible defects of ciliation.
Additionally, AIFþ/- HC mice presented immature “neuroblast” foci
with abnormal structures (Figure 4C). These structures, which nor-
mally disappear at the closure of the neural tube, indicated some
defects in the development of the AIFþ/- HC. The hydrocephalus mice
also had a bone structure problem, probably because of the cranial
cavity swelling provoked by the CSF pressure. No apoptotic features
were observed on the histological sections. AIFþ/- HC mice did not
exhibit apparent neurodegeneration and had a normal neuronal or-
ganization. Notably, a protein carbonylation immunoblot approach
performed on brain homogenates from 2.5-week-old animals revealed
that compared to AIFþ/þ and non-HC AIFþ/- females, the brain of the
AIFþ/- HC females displayed higher ROS levels (Figure 4D). This finding
suggested a relationship between ROS excess, generated by OXPHOS
dysfunction, and perinatal hydrocephaly. This hypothesis was
corroborated by the addition of an antioxidant (riboflavin) in the
drinking water of the dams, which significantly reduced the occurrence
of the AIFþ/- HC phenotype and microglial activation, detected by Iba1
immunolabeling, reflecting the inflammatory process provoked by
brain squeezing (Figure 4E,F). The mobility of riboflavin-treated AIFþ/-
females also appeared normal, indicating that the addition of an
antioxidant in the drinking water of AIFþ/- mice rescues the WT
phenotype.
3.5. AIF loss in mouse embryo induced midgestation lethality
associated with energy loss, proliferation arrest, and increased
apoptosis
Next, we attempted to generate AIF KO mice by crossing the non-HC
AIFþ/- females with WT males. This crossing generated AIFþ/þ and
AIFþ/Y animals, suggesting embryonic lethality of the AIF-/Y and AIFþ/-
progeny (Figure 5A, birth animals). Indeed, AIF-/Y male embryos pre-
sented normal development only until E7.5 (Figure 5A,B); then, they
displayed growth delay and arrested development between E8.5 and
E9.5, leading to embryo death at E11.5 (Figure 5A,B, and C). Female
AIFþ/- embryos exhibited inconstant developmental phenotypes and
died around E13.5 (Figure 5A).
We scrutinized mitochondrial and metabolic alterations associated with
the lethality of AIF-/Y embryos. An electronic microscopy approach
revealed highly fragmented mitochondria in E9.5 AIF-/Y embryosaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Figure 4: A significant percentage of AIFþ/- females developed a hydrocephalus phenotype associated with developmental defaults and an excess of mitochondrial
ROS. (A) To generate AIFþ/- animals, we crossed Aifm1 floxed males with PGK-Cre females. The table below indicates the offspring distribution. Approximately 10% of AIFþ/-
females developed a hydrocephalus (HC) phenotype. Photographs depict the phenotype of a 2.5-week-old AIFþ/- HC female and a HC brain compared to a WT brain. Note the
swelling of the cranial cavity of the mice and the excess of cerebrospinal fluid (CSF) that warps the HC brain. (B) Representative hematoxylin/eosin (HE)-labeled sections of 2.5-
week-old WT and AIFþ/- HC females showing (left to right) sagittal sections (entire mice and head) and coronal sections (brain and cerebellum). Note the extension of the hy-
drocephaly, the brain compression exerted by the CSF excess, and the herniated cerebellum in the AIFþ/- HC. (C) HE stained brain sections from 2.5-week-old AIFþ/- HC animals
showing spinal and parenchymatous hemorrhages and loss and defects of ciliation in the ependymal epithelium. Bar: 50 mm. (D) Oxidative modification of proteins assessed by
carbonylation immunoblot on brain homogenates from 2.5-week-old WT, AIFþ/-, and AIFþ/- HC mice. This experiment was repeated 3 times with similar results. The OD ratio
depicted in the graph illustrates the levels of protein carbonylation of the different phenotypes. Results are expressed as a ratio of OD relative to WT cells (set at 1.0). (E) PGK-Cre
dams were supplied or not with riboflavin in drinking water (5 mg/L) and the number and genotype/phenotype of the progeny were assessed and reported in a table. (F)
Characteristic immunofluorescence images of brains from 2.5-week-old WT, AIFþ/- HC, and AIFþ/- mice supplied with riboflavin (AIFþ/- þ Rb), showing the microglial (Iba1
labeling) status. Individual cells were visualized by Hoechst (nuclear) co-staining. Bar: 200 mm. Statistical significance in (D) was calculated by a ManneWhitney test. Bars
represent mean  SEM.
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Figure 5: Mitochondrial AIF deficiency-induced murine embryonic lethality linked to OXPHOS deficiency and energy loss. (A) To generate AIF KO mice, we crossed AIFþ/-
females with C57BL/6 WT males. After genetic identification, the result of the crossing (progeny and E8.5 to E13.5 embryos) was reported in a table. (B) Light microscope images
of E7.5 to E9.5 AIFþ/Y and AIF-/Y embryos illustrating the progressive growth delay of the AIF KO embryos. Bar: 500 mm. (C) Hematoxylin/eosin staining performed on the sagittal
sections of E8.5 and E9.5 AIFþ/Y and AIF-/Y embryos, underlining the morphology and the abnormal nervous development of the AIF KO embryos. Bar: 500 mm. (D) Electron
microscopy picturing mitochondria of E9.5 AIFþ/Y and AIF-/Y embryos. Representative microphotographs are shown. Arrowheads in the picture mark the mitochondria. White
squares show characteristic mitochondria. Bar: 0.5 mm. (E) Immunoblot of AIF and key proteins of the ETC complexes I to V performed in whole protein extracts from E9.5 AIFþ/Y
and AIF-/Y embryos. Equal loading was confirmed by b-Actin probing. This experiment was repeated 4 times with similar results. (F) Representative results of the histochemical
assessment of mitochondrial OXPHOS activity in E9.5 AIFþ/Y and AIF-/Y embryos using cytochrome c oxidase/succinate dehydrogenase (COX/SDH) double labeling. Bar: 50 mm.
Whereas OXPHOS activity is normal in AIFþ/Y embryos, as demonstrated by the brown color of the section, AIF-/Y showed defective OXPHOS activity (absence of brown staining).
This experiment was repeated 3 times with similar results. (G) Total ATP levels recorded, as described in the Methods section, in E9.5 AIFþ/Y and AIF-/Y embryos (n ¼ 6). Results
are expressed as RLU (relative light units). (H) Lactate release measured, as described in the Methods section, in E9.5 AIFþ/Y and AIF-/Y embryos (n ¼ 6). Statistical significance in
(G) and (H) was calculated by the student t test. Bars represent mean  SEM.
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Original Article(Figure 5D). Immunoblot analysis of key mitochondrial ETC proteins
showed a dramatic reduction of NDUFA9 (complex I protein) and
COX4I2 (complex IV protein; Figure 5E). This was accompanied by an
impairment of mitochondrial OXPHOS, as demonstrated by COX/SDH
histochemical labeling (Figure 5F): indeed, sections from mutant E9.5
embryos did not show the dark staining characterizing OXPHOS
functionality. As a consequence of OXPHOS dysfunction, AIF-/Y em-
bryos exhibited very low ATP levels (Figure 5G). Surprisingly, as shown
by the low amount of lactate detected (Figure 5H), AIF-/Y embryos
appeared unable to reprogram their metabolism toward anaerobic
glycolysis, contrary to AIF-/Y MEFs (Figure 2). Moreover, histological
analysis showed that these mitochondrial/metabolic changes were
accompanied by a decrease in the proliferation rate starting at E.8.5
(Figure 6A) and by the enhancement of apoptosis at E.9.5 in AIF-/Y
embryos (Figure 6B).Figure 6: Embryonic AIF loss triggered the arrest of proliferation and enhancement
of AIFþ/Y and AIF-/Y embryos at E8.5 and E9.5. Photographs of the head of a representati
Hoechst fluorescence measured in a fixed surface. Data in the histogram represent mean
sections). (B) TUNEL staining of a PFA fixed cryosection of AIFþ/Y and AIF-/Y embryos at E8.5
Hoechst fluorescence measured in a fixed surface. Data in the histogram represent mean
sections). Statistical significance in (A) and (B) was calculated by the student t test. Bars
12 MOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. TFinally, considering the inability of the AIF-/Y embryos to reprogram
their metabolism toward anaerobic glycolysis, we attempted to
circumvent lethality by eliminating the excess ROS with riboflavin and
feeding the dams with an HFD in which the major source of energy
changed from carbohydrates to fatty acids, which have proved efficient
in other AIF-deficient models [65]. However, even in these alternative
conditions, we were unable to generate AIF-/Y and AIFþ/- animals
(Supplemental Fig. 6). Overall, these data corroborated the mito-
chondrial OXPHOS/metabolism dysfunction of AIF-/Y embryos, and their
incapacity to reprogram their metabolism to grow and differentiate.
4. DISCUSSION
By creating an AIF KO model that enables in vitro and in vivo analysis,
we provide insights into new cellular and developmental consequencesof cellular apoptotic levels. (A) BrdU immunofluorescence analysis of a frozen section
ve embryo. Bar: 500 mm. The BrdU labeling index was calculated as the ratio of BrdU/
 SEM (n ¼ ratio obtained in at least 5 different surfaces of 3 independent embryonic
and E9.5. Bar: 500 mm. The TUNEL labeling index was obtained as the ratio of TUNEL/
 SEM (n ¼ ratio obtained in at least 5 different surfaces of 3 independent embryonic
represent mean  SEM.
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of the loss of mitochondrial AIF. We show that AIF deficiency triggers
destabilization of the mitochondrial ETC complexes I and IV, leading to
supercomplex disorganization, mitochondrial transmembrane potential
loss, and high levels of ROS generation. AIF-/Y MEFs counterbalance
these OXPHOS alterations by a mitochondrial network reorganization
implicating a fusion process and the overexpression of the mito-
chondrial SOD2. A more accurate molecular analysis at the cellular,
embryonic, and adult mice levels indicates that the mitochondrial
OXPHOS dysfunction associated with AIF loss results in pleiotropic
effects: (i) at a cellular level, AIF-/Y MEFs boost their anaerobic
glycolytic metabolism and evolve toward a senescence phenotype. The
glycolytic phenotype is characterized by AMPK phosphorylation/acti-
vation, the overexpression of the glucose transporter GLUT-4, the
enhancement of glucose uptake, and anaerobic lactate generation. The
energy-sensing kinase AMPK and the glucose assimilation transporter
GLUT-4 play central roles in the glycolytic reprogramming of the AIF KO
MEFs. Based on these results, further research should analyze the
transcriptional drivers activated by AMPK to specifically modulate Glut-
4 expression and control the metabolic adaptive responses that run the
AIF-/Y MEFs toward senescence.
Concerning the senescent phenotype, the ROS excess associated with
OXPHOS dysfunction provokes overexpression of Tp53 and Cdkn1a,
genes associated with cell cycle arrest, as well as up-regulation of
P21, a protein that by provoking the activation/dephosphorylation of
pRB inhibits cell cycle progression. Strikingly, a small percentage of
AIF-/Y MEFs spontaneously proliferate. These cycling AIF KO MEFs
diminish the mitochondrial mass and regulate ROS levels, inactivating
the senescent pathway. Remarkably, the cycling AIF-/Y MEFs are
resistant to caspase-independent inducers, underlining the role of AIF
in this mode of PCD and avoiding the controversies in the literature on
the participation of AIF in cell death; (ii) in whole animal experiments,
we have confirmed that the AIF KO animals are embryonic lethal.
However, analysis of heterozygous AIFþ/- females originally uncovered
immune cell exhaustion and the development of perinatal hydro-
cephalus seemingly associated with an excess of mitochondrial ROS.
This phenotype is characterized by an excess of CSF, brain develop-
ment impairment, meningeal fibrosis, and medullar hemorrhages; (iii)
finally, we propose, based on our findings, that AIF-deficient embry-
onic lethality is linked to the inability of KO embryos to reprogram their
metabolism toward anaerobic glycolysis. This provokes dramatic ATP
loss, arrest in proliferation, and caspase-dependent embryo death.
The mitochondrial “pro-survival” function of AIF seems linked to its
role in the import and assembly of key proteins of the ETC complexes
[12,66]. Our results in MEFs and embryos, analyzed within the context
of the “plasticity” model of ETC supercomplex organization [8,41],
indicate that AIF loss provokes disorganization of the SC architecture,
OXPHOS deregulation, ROS overproduction, and very restricted ca-
pacity for mitochondrial ATP generation. However, AIF deficiency does
not fully yield defective mitochondria in MEFs, as demonstrated by the
assessment of individual mitochondrial complex activities, which
reveal a limited but still functional ETC (amytal inhibits the residual
complex I activity). Indeed, our data on the overgeneration of mito-
chondrial ROS in the absence of mitochondrial ATP generation strongly
suggest that the ETC of the AIF -/Y MEFs is somewhat functional, but
the loss of key complex I/IV proteins provokes an impairment. As a
consequence, the AIF KO mitochondria appear unable to generate the
electrochemical gradient essential to produce ATP, probably because
of a premature electron leakage (which generates the excess of ROS
detected). Surprisingly, this mitochondrial ETC dysfunction does not
lead to cell death. Instead, AIF-/Y MEFs reprogram their metabolism
toward AMPK/GLUT-4-mediated anaerobic glycolysis (to generateMOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comATP), overexpress ROS detoxifying enzymes (to regulate the excess of
ROS as much as possible), and activate an enzymatically controlled
senescent pathway. Therefore, it seems that MEFs have the plasticity
to respond to ETC weakening. By contrast, AIF-/Y embryos are unable to
perform this metabolic adaptive response and show a drastic devel-
opmental defect leading to death. What is the reason for the different
MEFs/embryo behavior? We could hypothesize that the in vitro
carbohydrate-enriched cell culture condition supports MEFs glycolytic
metabolic reprogramming. In vivo, a glycolytic versus OXPHOS
metabolic shift around E8.5 has been described to be essential for
embryonic survival and fetal development [67,68]. In AIF-/Y OXPHOS
dysfunctional embryos, this shift is probably impossible, yielding
inevitable embryonic death.
In addition to its mitochondrial OXPHOS function, AIF has a lethal role in
its translocation to the nucleus [18e21,69]. Strong evidence for an AIF
role in PCD has been provided by studies performed with many cell
death models [21,22,70e76]. Despite this substantial amount of work,
some controversy remains regarding AIF function in PCD. Indeed,
studies performed in HeLa cells, SV40-immortalized MEFs, or with
caspase-dependent apoptotic inducers, have raised doubts about the
apoptogenic AIF potential [14,77,78]. We attempted to elucidate this
controversy by verifying the response to typical caspase-dependent
and independent inducers in non-transformed WT, AIF-/Y, and AIF
KO þ AIF reconstituted cells. We observed that AIF-/Y MEFs are
significantly resistant to treatment with MNNG and b-Lapachone,
classical caspase-independent PCD inducers, but they remain sensi-
tive to caspase-dependent apoptotic drugs. Although a more
exhaustive study is required, our results already indicate that the
contradictory results on the role AIF plays in PCD could be merely
associated with the cellular system employed or the type of PCD
inducer tested. In any case, the phenotype of AIF-/Y MEFs confirms the
essential role of AIF in the control of caspase-independent pro-
grammed cell death.
Genetic inactivation of AIF provokes embryonic death. Consequently,
generating an AIF KO progeny is not possible. Other studies in
embryoid bodies have suggested that AIF could regulate the initial
stages of murine development by controlling the cell death process of
cavitation [79]. However, in the study, we show that AIF-/Y embryos
develop normally until E7.5 and are morphologically indistinguishable
from WT embryos. By E8.5, AIF-/Y embryos are delayed compared to
WT littermates. Between E8.5 and E9.5, they stop growing, do not turn,
and have abnormal brain development. AIF-/Y embryos die at around
E11.5. These results are consistent with another study indicating that
AIF and the mitochondrial OXPHOS are not required at the initial stages
of mouse development [52]. However, in contrast to this work, we have
observed the arrest of proliferation and enhancement of PCD in E8.5
and E9.5 AIF-/Y embryos. In addition, we have observed that OXPHOS
dysfunction associated with AIF loss and the incapacity to perform
metabolic reprogramming seemed key to the embryonic lethality
associated with AIF deficiency.
Further research could help to understand why it is possible to
generate AIFþ/- offspring from AIFFl/Y; PGK-Cre cross, whereas the
resulting AIFþ/- females are unable to generate heterozygous AIF
progeny. An exciting possibility is the existence of bias in the timing or
strength of allele expression depending on the paternal or maternal
origin of the X chromosome. Notably, our data suggest that the E8.5
“embryonic-shift” from anaerobic to aerobic metabolism can only
occur when the female transmits the WT allele. This has no incidence
in the AIFFl/Y and PGK-Cre crossing (having an AIF KO allele generated
by PGK-Cre in the floxed X chromosome from the male). In the case of
the progeny of AIFþ/- females, the AIF KO allele transmitted by theaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 13
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the death of the AIFþ/- and AIF-/Y embryos. A second possibility, with
similar embryonic death consequences, is the implication of Aifm1 in
the particular behavior of the paternal X chromosome (Xp). Indeed, it
has been well documented that the Xp chromosome is preferentially
inactivated during the first stages of mice development [80,81].
Similarly, there is evidence that some genes are initially expressed
from the maternal allelic form [82]. In our case, the Aifm1-mutated
maternal allelic form would not be able to generate AIF. If Aifm1 was
also inactivated in Xp, the mitochondria of the AIFþ/- and AIF-/Y em-
bryos would be dysfunctional and, consequently, the embryo would not
be viable. What supports this second possibility is the morphological
analysis of the mitochondria from the AIF-mutated embryo (Figure 5D
and Supplemental Fig. 7), which reveals the irregular structure asso-
ciated with mitochondrial dysfunction [35].
The AIFþ/- females show 2 relevant pathological phenotypes: (i) im-
mune exhaustion in the adult animals and (ii) a perinatal hydrocephalus
phenotype. Concerning the alterations in the immune system associ-
ated with AIF, an initial study was performed with the Hq strain. In this
study, low AIF expression led to the high susceptibility of T-cell blasts
to activation-induced cell death and reduced sensitivity to neglect-
induced cell death. Moreover, thymocytes from Hq mice exhibited
higher ROS levels, which impacted thymocyte and T-cell development
[31,83]. A more specific work in which Aif was ablated around the DN3
stage of thymocyte development reported that AIF loss had no impact
on T-cell development. The use of the CD19-cre mice strain indicated
that AIF was not required for B-cell development and function [14]. Our
recent work, performed in a bona fide hematopoietic AIF KO strain,
where the protein was ablated very early during hematopoiesis,
revealed a greater role for AIF in immune cell fate [35,36]. Indeed, the
loss of AIF provoked progressive exhaustion of the HSC pool and
developmental defaults in the thymocyte, T-cell, B-cell, and erythroid
lineages. In agreement with these results, we observed
progressive cellular exhaustion in the bone marrow, spleen, and
thymus of the AIFþ/- females, fully corroborating the relevance of AIF in
the fine-tuning of the immune system.
Unreported in the literature is the hydrocephalus phenotype observed
in approximately 10% of AIFþ/- newborns. The signs of AIFþ/- hy-
drocephaly are readily apparent in young animals that develop the
disease before the cranial sutures close (allowing for an enlarged and
domed head). This is accompanied by a progressive loss of animal
mobility, and the cause is that the brain is completely encased within
the bony calvarium. The build-up of CSF causes tissue inflammation
(depicted by the microglial activation), hemorrhages of the surrounding
brain tissue, enlargement of the ventricles, and herniation of the brain
and cerebellum. In a general perspective, hydrocephalus may be
caused by blockage of the normal flow of CSF, failure to absorb CSF, or
less commonly, overproduction of CSF. CSF circulates throughout the
ventricular brain system through the motion of the ciliated ependymal
cells that line the ventricles.
In AIFþ/- HC, ependymal epithelium was absent from the edge of the
ventricles and consequently presented a loss of ciliation. Thus, similar
to what has been described in other mice strains [84e88], we pro-
pose that AIFþ/- hydrocephalus is caused by defects of the normal
CSF flow associated with the loss of ciliated ependymal cells. This
cellular loss appears to be directly related to the excess of ROS
detected in the brain homogenates of the AIFþ/- HC animals. Indeed,
external control of ROS excess through the supply of riboflavin to the
dams and newborns is sufficient to reduce this phenotype to the
standards of the C57BL/6J strain [89]. Notably, riboflavin was given to
patients with mitochondrial myopathy because of OXPHOS deficiency14 MOLECULAR METABOLISM 40 (2020) 101027  2020 The Author(s). Published by Elsevier GmbH. T[90e92]. Notably, riboflavin is a precursor to FMN and FAD, which are
cofactors of ETC complexes I and II, respectively. Riboflavin has been
proposed to act therapeutically through several potential mechanisms
including ROS control and inhibition of the breakdown of complex I by
providing more resistance to proteolysis or stabilizing the mitochon-
drial membrane [92].
5. CONCLUSION
Our data reveal that the mitochondrial signals regulated by AIF are
critical to cellular decision-making. Emerging as a link between
mitochondrial metabolism, mouse development, and cell fate, AIF-
mediated OXPHOS regulation represents a potential target in the
development of new therapeutic approaches. Indeed, further knowl-
edge of how the cells can modify their metabolic pathways may enable
their manipulation; ultimately, this might lead to new treatment options
for diseases in which the mitochondrial OXPHOS alteration/dysfunction
has an instrumental role.
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